Tumour-associated macrophages (TAMs) play an important role in the tumour environment and were reported to be associated with poor prognosis in several tumours. However, the prognostic significance of TAMs in Non-Hodgkin's Lymphoma (NHL) remains controversial. Consequently, we aimed to evaluate the relationship between subpopulations of TAMs and clinical outcomes in NHL patients. We did a comprehensive search of the PubMed, elsevier ScienceDirect, and Cochrane databases and extracted hazard ratio (HR) and their corresponding 95% confidence intervals (95% CIs) from eligible studies. Pooling total effect value by the stata statistical software and analysing correlation of TAMs with overall survival (OS) and progression-free survival (PFS). Furthermore, subgroup analysis and sensitivity analysis were also conducted. We deemed eleven studies, including 1211 NHL patients. Our study demonstrated that high-density CD68+ TAMs are associated with poor OS (HR: 1.17; 95% CI, 0.81-1.54; P = .000) and poor PFS (HR: 1.15; 95% CI, 0.63-1.67; P = .000) compared with low-density CD68+ TAMs in the tumour microenvironment. Similarly, high-density CD163+ TAMs can also predict poor OS (HR: 1.52; 95% CI, 1.11-1.92; P = .000) and shorter PFS (HR: 1.52; 95% CI, 0.73-2.30; P = .000). In addition, the high CD163+ /CD68+ TAMs ratio is significantly correlated with poor OS (HR: 3.59; 95% CI, 0.77-6.40; P = .013). However, in our subgroup analysis, high-density CD68+ TAMs in the tumour microenvironment is associated with better OS (HR: 0.75; 95% CI, 0.41-1.09; P = .000) in NHL patients treated with rituximab chemotherapy. Our results suggest that TAMs are a robust predictor of outcomes in NHL.

中文翻译：

---

肿瘤相关巨噬细胞在非霍奇金淋巴瘤中的预后价值：系统评价和荟萃分析。

肿瘤相关巨噬细胞（TAM）在肿瘤环境中起重要作用，据报道与几种肿瘤的不良预后有关。然而，TAMs在非霍奇金淋巴瘤（NHL）中的预后意义仍然存在争议。因此，我们旨在评估THLs亚群与NHL患者临床预后之间的关系。我们对PubMed，elsevier ScienceDirect和Cochrane数据库进行了全面搜索，并从合格研究中提取了危险比（HR）及其相应的95％置信区间（95％CI）。通过Stata统计软件汇总总效应值，并分析TAM与总体生存期（OS）和无进展生存期（PFS）的相关性。此外，还进行了亚组分析和敏感性分析。我们认为有11项研究，包括1211名NHL患者。我们的研究表明高密度CD68 + TAM与OS不良（HR：1.17; 95％CI，0.81-1.54; P = .000）和PFS不良（HR：1.15; 95％CI，0.63-1.67; P = .000）与肿瘤微环境中低密度CD68 + TAM的比较。同样，高密度CD163 + TAM也可以预测较差的OS（HR：1.52; 95％CI，1.11-1.92; P = .000）和较短的PFS（HR：1.52; 95％CI，0.73-2.30; P = .000 ）。此外，高CD163 + / CD68 + TAMs比率与不良OS显着相关（HR：3.59； 95％CI，0.77-6.40； P = 0.013）。但是，在我们的亚组分析中，在接受利妥昔单抗化疗的NHL患者中，肿瘤微环境中高密度CD68 + TAM与更好的OS（HR：0.75； 95％CI，0.41-1.09； P = .000）相关。我们的结果表明，TAM是NHL结局的有力预测指标。